Skip to main content
Premium Trial:

Request an Annual Quote

Mosaic Licenses DNA Bridge Technology to Affymax Technologies

Premium

BOSTON--Mosaic Technologies announced that it has granted a license and option relating to its patented Bridge amplification technology to Affymax Technolo gies, a wholly owned subsidiary of Glaxo Wellcome. The platform has broad applications in genomics-based drug development and pharmacogenomics, Mosaic said. Bridge amplification helps reduce time and expense by defining the genomic component and targeting the appropriate patient population, the company claimed.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.